1. Search Result
Search Result
Results for "

Wdr5-MLL

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12220A
    MM-102 TFA
    4 Publications Verification

    HMTase Inhibitor IX TFA

    WDR5 Cancer
    MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.
    MM-102 TFA
  • HY-16994

    WDR5 Cancer
    OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .
    OICR-0547
  • HY-153331

    WDR5 Cancer
    DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research .
    DDO-2213
  • HY-157659

    WDR5 Others
    WDR5-MLL1 antagonist 1 (compound 47) is a compound optimized through protein crystal structure guidance. It has stronger antagonistic activity against WDR5-MLL interaction with a dissociation constant (Kd) of 0.3μM.
    WDR5-47
  • HY-148817

    WDR5 Cancer
    WDR5-0102 is an inhibitor of WDR5. WDR5-0102 specifically targets the WIN site of WDR5, disrupts the WDR5-MLL1 interaction, and reduces the histone methyltransferase activity of MLL1. WDR5-0102 exerts dose-dependent toxicity on MDSC-like cells and reduces their osteopontin levels, while showing extremely low cytotoxicity to pancreatic cancer cells. WDR5-0102 can be used in the research of related diseases such as acute myeloid leukemia, lymphoid leukemia, biphenotypic leukemia and pancreatic cancer .
    WDR5-0102
  • HY-178751

    WDR5 Cancer
    Z116334910 is a promising WDR5-MLL1 interaction disruptor. Z116334910 can be used for the study of cancer .
    Z116334910
  • HY-178752

    WDR5 Cancer
    Z88418521 is a ligand for the WDR5-MLL1 complex. Z88418521 may help disrupt the interaction of the WDR5-MLL1 complex. Z88418521 can be used in cancer research, especially in leukemia .
    Z88418521
  • HY-168475

    Apoptosis WDR5 HDAC Cancer
    DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. DD0-2363 inhibits cells proliferation and induces apoptosis in acute myeloid leukemia cells. DD0-2363 has antitumor activity and can be used in the research of acute myeloid leukemia .
    DD0-2363
  • HY-183959

    WDR5 Cancer
    DC_M5_2 is a WD40 repeat domain protein 5 (WDR5) inhibitor with an IC50 of 9.63 μM and a KD of 13.8 μM. DC_M5_2 binds to the WDR5 pocket that interacts with the MLL1 peptide, blocking the WDR5-MLL1 protein-protein interaction . DC_M5_2 can be used in leukemia-related research .
    DC_M5_2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: